Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer

2001 ◽  
Vol 32 (8) ◽  
pp. 803-807 ◽  
Author(s):  
Avi Eisenthal ◽  
N. Polyvkin ◽  
L. Bramante–Schreiber ◽  
F. Misonznik ◽  
A. Hassner ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Dendritic Cells ◽  
Clinical Outcome ◽  
Ovarian Tumors

scholarly journals Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: lack of association with clinical outcome

1998 ◽  
Vol 78 (12) ◽  
pp. 1645-1652 ◽  
Author(s):  
G Ferrandina ◽  
G Scambia ◽  
A Fagotti ◽  
G D'Agostino ◽  
P Benedetti Panici ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Outcome ◽  
Cathepsin D ◽  
Immunohistochemical Analysis

scholarly journals The effect of prophylactic bilateral salpingectomy on ovarian reserve in patients who underwent laparoscopic hysterectomy

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Shizhuo Wang ◽  
Jiahui Gu
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Reserve ◽  
Premenopausal Women ◽  
Laparoscopic Hysterectomy ◽  
Ovarian Tumors ◽  
Reproductive Age ◽  
Control Group ◽  
Significant Difference ◽  
Bilateral Salpingectomy ◽  
The Impact

Abstract Background Bilateral salpingectomy has been proposed to reduce the risk of ovarian cancer, but it is not clear whether the surgery affects ovarian reserve. This study compares the impact of laparoscopic hysterectomy for benign disease with or without prophylactic bilateral salpingectomy on ovarian reserve. Methods Records were reviewed for 373 premenopausal women who underwent laparoscopic hysterectomy with ovarian reserve for benign uterine diseases. The serum anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and three-dimensional antral follicle count (AFC) were assessed before surgery and 3 and 9 months postoperatively to evaluate ovarian reserve. Patients were divided into two groups according to whether they underwent prophylactic bilateral salpingectomy. The incidence of pelvic diseases was monitored until the ninth month after surgery. Results There was no significant difference between the two surgery groups in terms of baseline AMH, E2, FSH, LH, and AFC (all P > 0.05). There was no difference in potential bias factors, including patient age, operative time, and blood loss (all P > 0.05). There was also no significant difference between the two groups 3 months after surgery with respect to AMH (P = 0.763), E2 (P = 0.264), FSH (P = 0.478), LH (P = 0.07), and AFC (P = 0.061). Similarly, there were no differences between groups 9 months after surgery for AMH (P = 0.939), E2 (P = 0.137), FSH (P = 0.276), LH (P = 0.07) and AFC (P = 0.066). At 9 months after the operation, no patients had malignant ovarian tumors. The incidences of benign ovarian tumors in the salpingectomy group were 0 and 2.68 % at 3 and 9 months after surgery, respectively, and the corresponding values in the control group were 0 and 5.36 %. The incidences of pelvic inflammatory disease in the salpingectomy group were 10.72 and 8.04 % at 3 and 9 months after surgery, respectively, while corresponding values in the control group were 24.13 and 16.09 %. Conclusions Prophylactic bilateral salpingectomy did not damage the ovarian reserve of reproductive-age women who underwent laparoscopic hysterectomy. Prophylactic bilateral salpingectomy might be a good method to prevent the development of ovarian cancer. Larger clinical trials with longer follow-up times are needed to further evaluate the risks and benefits.

scholarly journals A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer

2013 ◽  
Vol 11 (1) ◽  
pp. 149 ◽  
Author(s):  
Lana E Kandalaft ◽  
Cheryl L Chiang ◽  
Janos Tanyi ◽  
Greg Motz ◽  
Klara Balint ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Dendritic Cells ◽  
Phase I ◽  
Vaccine Trial ◽  
Recurrent Ovarian Cancer

scholarly journals COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer

Oncogene ◽  
2013 ◽  
Vol 33 (26) ◽  
pp. 3432-3440 ◽  
Author(s):  
Y-H Wu ◽  
T-H Chang ◽  
Y-F Huang ◽  
H-D Huang ◽  
C-Y Chou
Keyword(s):  
Ovarian Cancer ◽  
Clinical Outcome ◽  
Tumor Progression ◽  
Poor Clinical Outcome
Sign in / Sign up

Export Citation Format

Share Document